Clinical trial · Interventional
Epidural Analgesia Use in Pancreatic Resections
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The rationale for this study is to investigate the benefits of epidural analgesia in pancreatic resections in a prospective, single blind, randomized control trial. This study will evaluate both short and long-term outcomes related to epidural analgesia, providing a longitudinal and comprehensive perspective to the advantages and disadvantages of this technique. The investigators hypothesize that the use of epidural analgesia reduces a patient's consumption of morphine or morphine-equivalent in the post-operative period following pancreatic resections.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cancer of Pancreas | Malignant Pancreatic Neoplasm | ALIAS | 0.90 |
| Cancer of the Pancreas | Malignant Pancreatic Neoplasm | ALIAS | 0.90 |
| Pancreas Cancer | Pancreatic Carcinoma | ALIAS | 0.90 |
| Pancreas Neoplasms | Pancreatic Neoplasm | ALIAS | 0.90 |
| Pancreatic Cancer | Malignant Pancreatic Neoplasm | CURATED_EXACT | 0.92 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Bupivacaine | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- EXPERIMENTAL
- label
- Study: Bupivacaine Epidural + standard of care pain regimen
- description
- -The study group will receive a T6 to T8 level epidural catheter in addition to the standardized pain regimen. Epidurals used in this study will contain a 0.125% bupivacaine-only infusion
- interventionNames
- Drug: Bupivacaine
- type
- NO_INTERVENTION
- label
- Control: Standard of care pain regimen
- description
- -The control group will receive a standardized pain regimen including an opioid patient controlled analgesia (PCA), IV acetaminophen, and IV ketorolac per surgeon's preference
Primary outcomes (1)
- measure
- Total consumption of morphine or morphine-equivalent in patients undergoing pancreatic resections in the control group compared with the study group
- timeFrame
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Undergoing pancreatic resection. * Age ≥18 years old. * Able to understand and sign an Institutional Review Board (IRB)-approved informed consent form. Exclusion Criteria: * Indication for operative intervention being chronic pancreatitis. * Currently on warfarin with an INR≥1.4 or clopidogrel that cannot be discontinued 7 days prior to surgery; * Most recent INR prior to surgery \>1.4 * Most recent platelet count prior to surgery \<70,000/mcl * Chronic opioid use as defined by use of more than 20mg oxycodone, or equivalent, daily. * History of pre-existing neuropathic pain conditions. * Not giving consent for study participation. * Known medical history of significant psychiatric or cognitive impairment * History of HIV, Hepatitis B, and/or Hepatitis C
References
Publications (1)
- DERIVEDPak LM, Haroutounian S, Hawkins WG, Worley L, Kurtz M, Frey K, Karanikolas M, Swarm RA, Bottros MM. Epidurals in Pancreatic Resection Outcomes (E-PRO) study: protocol for a randomised controlled trial. BMJ Open. 2018 Jan 26;8(1):e018787. doi: 10.1136/bmjopen-2017-018787. PMID 29374667